Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Director James A. Geraghty acquired 10,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were bought at an average price of $4.82 per share, for a total transaction of $48,200.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $48,200. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Pieris Pharmaceuticals, Inc. (PIRS) traded down 2.32% on Thursday, hitting $4.63. 388,394 shares of the stock traded hands. Pieris Pharmaceuticals, Inc. has a 52 week low of $1.30 and a 52 week high of $6.20. The stock’s market cap is $205.15 million. The firm’s 50 day moving average is $5.34 and its 200 day moving average is $3.65.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Pieris Pharmaceuticals, Inc. (PIRS) Director Acquires 10,000 Shares of Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/17/insider-buying-pieris-pharmaceuticals-inc-pirs-director-acquires-10000-shares-of-stock.html.

Several research analysts have recently issued reports on PIRS shares. Rodman & Renshaw started coverage on shares of Pieris Pharmaceuticals in a report on Tuesday, May 30th. They set a “buy” rating and a $9.00 price objective on the stock. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. TheStreet upgraded shares of Pieris Pharmaceuticals from a “d” rating to a “c-” rating in a report on Wednesday, May 3rd. Finally, HC Wainwright set a $9.00 price objective on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 11th. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $8.25.

Several hedge funds have recently bought and sold shares of PIRS. California State Teachers Retirement System bought a new stake in Pieris Pharmaceuticals during the second quarter worth about $308,000. The Manufacturers Life Insurance Company boosted its stake in Pieris Pharmaceuticals by 1,106.3% in the second quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after buying an additional 29,150 shares in the last quarter. State Street Corp bought a new stake in Pieris Pharmaceuticals during the second quarter worth about $2,377,000. Voya Investment Management LLC bought a new stake in Pieris Pharmaceuticals during the second quarter worth about $100,000. Finally, Vanguard Group Inc. bought a new stake in Pieris Pharmaceuticals during the second quarter worth about $526,000. Institutional investors own 45.34% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.